Condition

Diffuse Large B-cell Lymphoma

ClinicalTrials.gov condition label

Clinical trials7

Recruiting0

Common interventions12

Lead sponsors shown7

Clinical trials

7 shown

A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced CancersNCT06870487 · 2025-05-08

A Safety Study of SEA-TGT (SGN-TGT) in Advanced CancerNCT04254107 · 2020-05-29

A Safety and Tolerability Study of INCAGN02385 in Select Advanced MalignanciesNCT03538028 · 2018-06-18

Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell LymphomaNCT02660710 · 2016-03-01

A Long-term Extension Study of PCI-32765 (Ibrutinib)NCT01804686 · 2013-09-09

ACTIVE_NOT_RECRUITING

BMS_PD-L1_onco : Assessment of the PD-L1 Protein as a Biomarker in Oncology and HematologyNCT01660776 · 2012-06-07

Assessment of Cellular Proliferation in Tumors by Positron Emission Tomography (PET) Using [18F]ISO-1NCT00968656 · 2009-01-01

Common interventions

SasanlimabDRUG2 brentuximab vedotinDRUG1 F-18-ISODRUG1 IbrutinibDRUG1 Immunohistochemistry stainingOTHER1 INCAGN02385BIOLOGICAL1 Laboratory TestingOTHER1 PET/CTRADIATION1 PF-08046032DRUG1 R-CHOPDRUG1 Safety TestingOTHER1 SEA-TGTDRUG1

Leading sponsors

Incyte Biosciences International Sàrl1 Janssen Research & Development, LLC1 Pfizer1 Rennes University Hospital1 Seagen Inc.1 UNC Lineberger Comprehensive Cancer Center1 Washington University School of Medicine1

Trial status mix

COMPLETED4

TERMINATED2

ACTIVE_NOT_RECRUITING1

Phase mix

PHASE14

PHASE21

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.